176 related articles for article (PubMed ID: 37027809)
1. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
2. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
Ellingson BM; Sampson J; Achrol AS; Aghi MK; Bankiewicz K; Wang C; Bexon M; Brem S; Brenner A; Chowdhary S; Floyd JR; Han S; Kesari S; Randazzo D; Vogelbaum MA; Vrionis F; Zabek M; Butowski N; Coello M; Merchant N; Merchant F
Clin Cancer Res; 2021 Jul; 27(14):3916-3925. PubMed ID: 33863808
[TBL] [Abstract][Full Text] [Related]
3. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
[TBL] [Abstract][Full Text] [Related]
4. A Comparative Retrospective Study of Immunotherapy RANO
Chen X; Lim-Fat MJ; Qin L; Li A; Bryant A; Bay CP; Gao L; Miskin N; Liu Z; Iorgulescu JB; Xu X; Reardon DA; Young GS
Front Oncol; 2021; 11():679331. PubMed ID: 34249718
[TBL] [Abstract][Full Text] [Related]
5. MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.
Heugenhauser J; Galijasevic M; Mangesius S; Goebel G; Buchroithner J; Erhart F; Pichler J; Widhalm G; Stockhammer G; Iglseder S; Freyschlag CF; Oberndorfer S; Bordihn K; von Campe G; Czech T; Surböck B; Urbanic Purkart T; Marosi C; Felzmann T; Nowosielski M
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326730
[TBL] [Abstract][Full Text] [Related]
6. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Youssef G; Wen PY
Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
[TBL] [Abstract][Full Text] [Related]
7. Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.
Hoff BA; Lemasson B; Chenevert TL; Luker GD; Tsien CI; Amouzandeh G; Johnson TD; Ross BD
Acad Radiol; 2021 Dec; 28(12):1711-1720. PubMed ID: 32928633
[TBL] [Abstract][Full Text] [Related]
8. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
10. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
11. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
[TBL] [Abstract][Full Text] [Related]
12. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
13. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
14. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
15. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria.
Roh YH; Park JE; Kang S; Yoon S; Kim SW; Kim HS
Cancer Imaging; 2023 Oct; 23(1):102. PubMed ID: 37875970
[TBL] [Abstract][Full Text] [Related]
17. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
18. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
[TBL] [Abstract][Full Text] [Related]
19. Early imaging marker of progressing glioblastoma: a window of opportunity.
Gatson NTN; Bross SP; Odia Y; Mongelluzzo GJ; Hu Y; Lockard L; Manikowski JJ; Mahadevan A; Kazmi SAJ; Lacroix M; Conger AR; Vadakara J; Nayak L; Chi TL; Mehta MP; Puduvalli VK
J Neurooncol; 2020 Jul; 148(3):629-640. PubMed ID: 32602020
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Okada H; Weller M; Huang R; Finocchiaro G; Gilbert MR; Wick W; Ellingson BM; Hashimoto N; Pollack IF; Brandes AA; Franceschi E; Herold-Mende C; Nayak L; Panigrahy A; Pope WB; Prins R; Sampson JH; Wen PY; Reardon DA
Lancet Oncol; 2015 Nov; 16(15):e534-e542. PubMed ID: 26545842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
